Overview

Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the levels of immune and inflammatory markers among HIV-1, HSV-2 co-infected adults achieving plasma HIV RNA suppression to <50 copies/mL, between those randomized to valacyclovir and placebo, over a twelve-week intervention period.

Phase:

Phase 3

Details

Lead Sponsor:

University Health Network, Toronto

Collaborators:

Canadian Institutes of Health Research (CIHR)
University of Toronto

Treatments:

Acyclovir
Valacyclovir